Four Square Players
- 203,851 have read Four Square Clobbers Cancer
Sign Up Today!Want to get the latest articles from Four Square Clobbers Cancer? Enter your email below and you will get all of the latest updates.
- Thankful and Fearful
- Every 2 minutes?
- Jace Ward’s Friends Can’t Wait
- Think about others
- Collaboration to Cure Medulloblastoma
- Two Little Words
- Turn Away… You may not want to hear this
- Cord Blood, a life line
- CAVATICA Genomics Data Sharing
- The Cancer Moonshot: Are Our Kids Stepping on the Moon Too?
- Broken Trust
- Fly Me to the Moon
- I Gladly Spoke Up for Kids With Cancer Today
- A 10 year old, Speaking from Experience
- Bereavement Meeting
Follow Four Square on TwitterMy Tweets
Missing Kylie by Mark Myers
Better Angels by Sadie Keller and Michael McCaul
The Truth 365 VideoIf you have not had a child suffer from cancer, you must watch this video to get the real picture of what it is like. It takes only 8 minutes, but it will be the best 8 minutes you will spend in order to understand what is happening to our kids and what we can do about it.
Click photo below to see The Truth365 Video
Tag Archives: pembrolizumab
Posted on December 21, 2014 by Team Captain
I am not sure how many people outside of the cancer research community know this, but it is well recognized that the human body is equipped to fight off cancer on its own. The same immune system that we have … Continue reading →
Posted in Cancer, Childhood Cancer, Pediatric Cancer, Rare Disease, Uncategorized | Tagged acute lymphoblastic leukemia, ALL CLL, American Society of Hematology, autoimmune disease, biotech, Bristol-Meyers Squibb, CAR, CAR T, CART, checkpoint inhibitor, chemotherapy, Children's Hospital of Philadelphia, chimeric antigen receptor, cytokines, DNA, Dr. Stephen Grupp, EGFG, FDA, Gardasil, HIV Aids, immunosupressive, immunotherapy, interferon, interleukins, Keytruda, Laurie Orloski, Leukemia, Melanoma, Merck, metastatic disease, molecularly targeted agents, New England Journal of Medicine, nivolumab, Novartis Pharmaceuticals, Opdivo with r symbol, PD-1, pembrolizumab, personalized medicine, pharma, pharmaceutical, small-molecule inhibitors, spontaneous remission, T-cells, toxicity, tyrosine kinase inhibitors (TKIs), University of Pennsylvania, vaccines | 1 Comment